Latanoprost/Timolol Teva (Timolol Maleate, Latanoprost)

The combination works through two complementary actions: Latanoprost increases uveoscleral outflow of aqueous humor by activating prostaglandin FP receptors, while Timolol reduces aqueous humor production by blocking β‑adrenergic receptors in the ciliary epithelium. Together they achieve a greater reduction in eye pressure than either component alone.

The prescribed regimen is determined by the treating ophthalmologist. Typically, one drop is instilled in the affected eye(s) once daily, but the exact dosing schedule, including the eye(s) treated and timing, should follow the clinician’s instructions.

Safety data are limited. The product should be used during pregnancy only if the potential benefit justifies any possible risk to the fetus. Likewise, breastfeeding mothers should consider the unknown excretion in milk and discuss risks with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with monotherapy agents such as latanoprost alone or timolol alone, the combination offers a greater intraocular pressure reduction because it targets both aqueous production and outflow. It is often preferred when a single agent does not achieve target pressure, whereas alternatives like brimonidine/timolol or fixed‑dose prostaglandin analogues provide different efficacy and side‑effect profiles.

Store the ophthalmic solution at room temperature, preferably below 25 °C, in the original bottle. Protect it from light and moisture, and keep the cap tightly closed when not in use. Do not freeze the product.

The medication is supplied as sterile eye drops. The patient should wash hands, tilt the head back, pull down the lower eyelid to form a pocket, and place one drop into the conjunctival sac of each prescribed eye. Close the eye gently for a few seconds and avoid blinking or rubbing. Do not touch the tip of the bottle to the eye or any surface.

Serious adverse events, although rare, include severe allergic reactions (angioedema, anaphylaxis), bronchospasm in susceptible individuals, marked bradycardia or hypotension, corneal ulceration, and intraocular inflammation such as uveitis. Patients should seek immediate medical attention if they experience difficulty breathing, rapid heartbeat, severe eye pain, vision changes, or signs of an allergic reaction.

The combination is contraindicated in patients with known hypersensitivity to latanoprost, timolol, or any excipients. It should also be avoided in individuals with severe asthma, chronic obstructive pulmonary disease, sinus bradycardia, second‑ or third‑degree heart block, or uncontrolled heart failure, unless a physician determines that the benefits outweigh the risks.